Zarco Montejo, Pedro http://orcid.org/0000-0002-3039-187X
Almodóvar González, Raquel http://orcid.org/0000-0001-6622-3993
De Higes-Martínez, Eva http://orcid.org/0000-0003-0546-7008
Gorgojo-Martínez, Juan José http://orcid.org/0000-0002-8679-0968
Guijarro Herraiz, Carlos http://orcid.org/0000-0001-8132-9366
López Navas, María Jesús http://orcid.org/0000-0001-9584-8263
Palacios, David http://orcid.org/0000-0003-4595-9365
Peláez Álvarez, Jose Carlos http://orcid.org/0000-0002-6302-9770
Ruíz Genao, Diana http://orcid.org/0000-0003-1093-6411
Piedrafita, Blanca http://orcid.org/0000-0003-3210-152X
Gómez, Susana http://orcid.org/0000-0002-5337-2970
Falkenbach, Erica http://orcid.org/0000-0002-0420-6781
Rebollo Laserna, Francisco Jose http://orcid.org/0000-0003-3651-3687
López Estebaranz, Jose Luis http://orcid.org/0000-0002-8816-1989
Funding for this research was provided by:
Pfizer España
Article History
Received: 28 February 2020
Accepted: 26 March 2020
First Online: 9 April 2020
Conflicts of interest
: The following authors have received consulting and/or speaker fees: PZM from Abbvie, Elli Lilly, MSD, Novartis, Pfizer and UCB Pharma; JLLE from Almirall, Galderma, Leo Pharma, Novartis, Abbvie, Pfizer, Elli Lilly, Janssen, Celgene and Isdin; DRG from Pfizer, LeoPharma, Novartis, Elli Lilly, Janssen, Celgene and Abbvie; RAG from Abbvie, Celgene, Gebro, Janssen, Eli Lilly, MSD, Novartis, Pfizer and UCB; JJGM from Astra-Zeneca, Janssen, Eli Lilly, MSD, Mundipharma, Novo-Nordisk, Pfizer; Abbott, AbbVie, Boehringer Ingelheim Pharmaceuticals, Esteve, Roche and Sanofi-Aventis; CGH from Amgen, Ferrer, MSD, Pfizer and Sanofi-Aventis; EDHM from Pfizer, AstraZeneca, GSK, Novartis, Esteve, Chiesi, Ferrer, Rovi, Mundipharma and Eli Lilly; JCPA from Pfizer, Shire Pharmaceuticals Iberica, MSD and Laboratorios Rovi. MJLN, DP and BP declare no conflict of interest. FJRL, EF and SG are employees of Pfizer Inc.